- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07598734
Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty
Doxepin Versus Doxepin and Ramelteon Versus Placebo to Improve Sleep Quality After Primary Total Knee Arthroplasty: A Randomized Controlled Trial
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 4
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Gerald Y Liao, MS
- Numer telefonu: 617-710-7211
- E-mail: liaog@uw.edu
Kopia zapasowa kontaktu do badania
- Nazwa: Nicholas M Hernandez, MD
- Numer telefonu: 530-514-1275
- E-mail: nichern@uw.edu
Lokalizacje studiów
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98133
- University of Washington Medical Center Hip & Knee Center
-
Kontakt:
- Portia Morgan
- Numer telefonu: 206-668-3674
- E-mail: morganp9@uw.edu
-
Główny śledczy:
- Nicholas M Hernandez, MD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Those receiving primary total knee arthroplasty (TKA)
- 80 years or less, age 18 or greater
Exclusion Criteria:
- History of cardiovascular bundle branch block
- Actively taking selecrtive serotoin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or having treatment via counseling/psychotherapy for major depression or anxiety, bipolar, or psychotic disorder
- Pre-operative narcotics (defined as more than 1 prescription in the past 3 months)
- Self-reported use of alcohol in excess of >2 drinks/day (in men) and > 1 drink/day (in women)
- Use of prescription sleep aids (e.g., Ambien, Trazadone) prior to surgery (i.e., melatonin or other OTC sleep aids are permitted)
- History of major sleep disorder (e.g., obstructive sleep apnea (OSA), restless leg syndrome, narcolepsy)
- Pregnant, breastfeeding or planning to become pregnant in the next 3 months post-surgery. No pregnancy testing will be performed; screening will rely solely on participant self-report.
- Unable to take the study medication(s) due to contraindications with other medications the patient uses
- Have been diagnosed with (or are at risk of) narrow-angle or angle-closure glaucoma. In order to be eligible, participants must be able to report that they have had their eyes dilated within the past year without problems.
- Have severe urinary retention or difficulty emptying your bladder.
- Had glaucoma-related eye procedures (e.g., laser iridotomy)
- Ongoing use of glaucoma eye drops.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Doxepin 6 mg
Participants receive doxepin 6 mg and matching placebo orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
|
Eksperymentalny: Doxepin 6 mg and Ramelteon 8mg
Participants receive doxepin 6 mg and ramelteon 8 mg orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
Ramelteon 8 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
|
Komparator placebo: Placebo
Participants receive 2 matching placebos orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
|
Placebo administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Insomnia Severity Index (ISI) scores (sleep quality)
Ramy czasowe: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Insomnia Severity Index (ISI) The Insomnia Severity Index is a 7-item self-reported questionnaire assessing the nature, severity, and impact of insomnia.
Score categories:
|
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS)
Ramy czasowe: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
|
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS): The KOOS-PS is a 7-item patient-reported outcome measure assessing knee-related physical function, including activities such as rising from bed, putting on socks, rising from sitting, bending to the floor, twisting/pivoting, kneeling, and squatting . Each item is scored on a 5-point Likert scale (None to Extreme). Scores are transformed to a normalized scale ranging from 0 to 100, with higher scores indicating worse physical function (greater disability). |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
|
|
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR)
Ramy czasowe: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR): The KOOS-JR is a patient-reported outcome measure assessing knee pain, stiffness, and functional limitations during activities of daily living over the past week, including tasks such as twisting/pivoting, stair navigation, standing, rising from sitting, and bending . The instrument consists of 7 items scored on a 5-point Likert scale (None to Extreme). Raw scores (range 0-28) are summed and converted to an interval score ranging from 0 to 100, where 0 represents total knee disability and 100 represents perfect knee health (higher scores indicate better outcomes) |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
|
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10)
Ramy czasowe: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10): The PROMIS-10 is a 10-item patient-reported outcome measure assessing global physical health, mental health, pain, fatigue, and social functioning. Items are scored on 5-point Likert scales (e.g., Excellent to Poor; Not at all to Very much), with one pain item scored from 0 to 10. Raw scores are summed and converted to standardized T-scores for Global Physical Health and Global Mental Health, each ranging approximately from 0 to 100 (mean 50, standard deviation 10), where higher scores indicate better health status |
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
90-Day Hospital Readmission Status
Ramy czasowe: Within 90 days postoperatively
|
Hospital readmission status within 90 days following primary total knee arthroplasty, defined as any unplanned inpatient admission to a hospital occurring within 90 days after the index procedure.
This is a dichotomous outcome (Yes/No), where "Yes" indicates that a readmission occurred and represents a worse outcome.
|
Within 90 days postoperatively
|
|
Medication Compliance
Ramy czasowe: 2 weeks postoperatively; 6 weeks postoperatively
|
Medication Compliance: Medication adherence assessed using patient self-report and pill counts when feasible. Self-reported adherence is measured by patient-reported proportion of prescribed doses taken, and pill counts are used to calculate the percentage of medication consumed relative to the prescribed amount. Adherence is expressed as a percentage from 0 to 100%, where higher values indicate better compliance. |
2 weeks postoperatively; 6 weeks postoperatively
|
|
Length of Stay (LOS)
Ramy czasowe: Perioperative/Periprocedural
|
Length of Stay (LOS): Length of hospital stay following primary total knee arthroplasty, defined as the number of days from hospital admission to discharge (continuous variable, ≥0 days), where higher values indicate longer hospitalization (worse outcome). |
Perioperative/Periprocedural
|
|
Discharge Destination
Ramy czasowe: Perioperative/Periprocedural
|
Discharge Destination: Discharge disposition following primary total knee arthroplasty, categorized as home versus skilled nursing facility. This is a categorical outcome where discharge to a skilled nursing facility represents a worse outcome compared to discharge home. |
Perioperative/Periprocedural
|
|
Postoperative Mobility (Step Count)
Ramy czasowe: Perioperative/Periprocedural
|
Postoperative Mobility (Step Count): Postoperative mobility assessed by the number of steps taken during inpatient physical therapy sessions following primary total knee arthroplasty. Step count is recorded as the total number of steps ambulated (continuous variable, ≥0), where higher values indicate better functional recovery. |
Perioperative/Periprocedural
|
|
Level of Assistance Required for Ambulation
Ramy czasowe: Perioperative/Periprocedural
|
Level of Assistance Required for Ambulation: Level of assistance required during inpatient physical therapy following primary total knee arthroplasty, categorized as independent, 1-person assist, 2-person assist, or maximal assist. This is an ordinal outcome where greater assistance requirements indicate worse functional recovery. |
Perioperative/Periprocedural
|
|
Postoperative Falls
Ramy czasowe: Perioperative/Periprocedural; 3 months postoperatively
|
Postoperative Falls: Occurrence of patient falls during hospitalization or within the follow-up period after primary total knee arthroplasty, defined as any unintentional descent to the ground or lower level documented in the medical record.
This is a dichotomous outcome (Yes/No), where "Yes" indicates a fall occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Delirium
Ramy czasowe: Perioperative/Periprocedural; 3 months postoperatively
|
Occurrence of delirium during hospitalization or follow-up after primary total knee arthroplasty, defined by clinical documentation of acute confusional state or use of delirium-related precautions (e.g., 1:1 sitter, physical restraints).
This is a dichotomous outcome (Yes/No), where "Yes" indicates delirium occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
|
Pressure Ulcers (Bed Sores)
Ramy czasowe: Perioperative/Periprocedural; 3 months postoperatively
|
Pressure Ulcers (Bed Sores): Development of pressure ulcers during hospitalization or follow-up after primary total knee arthroplasty, defined as localized injury to the skin or underlying tissue documented in the medical record. This is a dichotomous outcome (Yes/No), where "Yes" indicates a pressure ulcer occurred and represents a worse outcome. |
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Opioid Consumption (Morphine Milligram Equivalents)
Ramy czasowe: Perioperative/Periprocedural; 3 months postoperatively
|
Postoperative Opioid Consumption (Morphine Milligram Equivalents): Total postoperative opioid use following primary total knee arthroplasty, calculated as cumulative morphine milligram equivalents (MME) administered during hospitalization and follow-up. This is a continuous variable (≥0 mg), where higher values indicate greater opioid consumption (worse outcome). |
Perioperative/Periprocedural; 3 months postoperatively
|
|
Postoperative Medical Complications
Ramy czasowe: Perioperative/Periprocedural
|
Postoperative Medical Complications: Occurrence of medical complications following primary total knee arthroplasty, including myocardial infarction, venous thromboembolism, cerebrovascular accident, acute kidney injury, respiratory failure, urinary tract infection, pneumonia, gastrointestinal obstruction, and need for intensive care unit (ICU) admission during the same hospitalization. This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome. |
Perioperative/Periprocedural
|
|
Postoperative Surgical Complications
Ramy czasowe: Perioperative/Periprocedural; 3 months postoperatively
|
Occurrence of surgical complications following primary total knee arthroplasty, including reoperation, periprosthetic fracture, dislocation, infection, and postoperative stiffness.
This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome.
|
Perioperative/Periprocedural; 3 months postoperatively
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Nicholas M Hernandez, MD, University of Washington
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- STUDY00024373
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Doxepin 6 mg
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin China Pharmaceutical Co., LTD.Zakończony
-
Adynxx, Inc.National Institute on Drug Abuse (NIDA)Wycofane
-
BioMarin PharmaceuticalZakończonyDystrofia mięśniowa Duchenne'aBelgia, Holandia, Włochy, Szwecja
-
University of PennsylvaniaTeva Branded Pharmaceutical Products R&D, Inc.Zakończony
-
Haitao Niu, MDZakończonyPacjenci z rakiem prostaty poddawani radykalnej prostatektomii | Prostata CAChiny
-
Chulalongkorn UniversityJeszcze nie rekrutacja
-
University of AarhusAarhus University HospitalZakończony
-
Weill Medical College of Cornell UniversityEisai Inc.Zakończony
-
BioMarin PharmaceuticalZakończonyDystrofia mięśniowa Duchenne'aHolandia, Belgia, Włochy, Szwecja
-
SunovionZakończony